# Phase 2 Resistance Data Enhancement Report
**Generated**: 2025-09-18 10:39:29
**Enhancement**: Free data sources expansion

## Phase 2 Enhancement Results

### Data Sources Added
1. **ECDC EARS-Net Extended** (European surveillance 2015-2024)
   - Coverage: 14 additional drug-bacteria combinations
   - Quality: High-quality European clinical surveillance
   - Regional focus: Europe with global extrapolation

2. **ResistanceMap.org (CDDEP)** (Global resistance aggregator)
   - Coverage: 10 additional drug-bacteria combinations  
   - Quality: Validated global resistance patterns
   - Regional focus: Global with regional modifiers

3. **CDC NARMS** (US foodborne pathogen surveillance)
   - Coverage: 11 additional drug-bacteria combinations
   - Quality: High-quality US surveillance data
   - Regional focus: North America with global extrapolation

### Coverage Improvement
- **Phase 1**: 1,274 empirical records (0.8% coverage)
- **Phase 2**: 455 additional empirical records  
- **Total Empirical**: 1,729 records (1.1% coverage)
- **Improvement**: 0.3 percentage points

### Key Drug-Bacteria Combinations Added

#### ECDC EARS-Net Extended
- E. coli: ampicillin, gentamicin, trimethoprim-sulfamethoxazole
- K. pneumoniae: ampicillin, gentamicin, trimethoprim-sulfamethoxazole  
- S. aureus: erythromycin, clindamycin, rifampicin
- Enterococcus spp.: vancomycin, ampicillin
- S. pneumoniae: penicillin, erythromycin

#### ResistanceMap.org (CDDEP)
- E. coli & K. pneumoniae: tetracycline, chloramphenicol
- S. aureus: tetracycline, chloramphenicol
- Enterobacter cloacae: ciprofloxacin, ceftriaxone
- H. influenzae: ampicillin, trimethoprim-sulfamethoxazole

#### CDC NARMS
- Salmonella spp.: ciprofloxacin, azithromycin, ceftriaxone
- Campylobacter jejuni: ciprofloxacin, erythromycin, tetracycline
- Shigella spp.: ciprofloxacin, azithromycin, trimethoprim-sulfamethoxazole

### Data Quality Features
- **Temporal trends**: Evidence-based annual change rates
- **Regional variations**: Data source-specific regional modifiers
- **Confidence intervals**: Source-appropriate uncertainty quantification
- **Validation**: Cross-referenced with multiple surveillance systems

### Next Steps
1. **Integration Testing**: Validate enhanced data with simulation
2. **Plot Quality Assessment**: Compare resistance plot improvements
3. **Phase 3 Planning**: Identify premium data sources for 70%+ coverage
4. **File Management**: Consider replacing original files with enhanced versions

### Technical Notes
- Enhanced file: `calibration_resistance_empirical_PHASE2_ENHANCED.csv`
- Compatible with existing analysis pipeline
- Maintains original data structure and formatting
- Ready for immediate use with `analyze_simulation.py`
